Searched for: in-biosketch:true
person:vso201
Poliosis, hair pigment dilution, and premature graying of the hair: A diagnostic approach in pediatric patients and review of the literature
Rangu, Sneha A; Oza, Vikash S
Poliosis is defined as the absence of melanin in hair, and hair graying typically occurs with hair melanin reduction. Poliosis can occur at any age but presents in childhood in certain genetic and acquired conditions, with many families seeking evaluation from a pediatric dermatologist. Poliosis presents as white hair typically restricted to a certain location of the scalp. Children may also present with a reduction of expected hair pigmentation, referred to as pigment dilution, or the development of hair graying. This review aims to provide a streamlined diagnostic approach for pediatric dermatologists when presented with these hair findings. Poliosis should be recognized as a potential diagnostic feature or initial sign in many syndromes and thus can guide clinicians in diagnosing and managing conditions earlier in a patient's care. Since many of the genetic and acquired conditions that present with poliosis or hair pigment dilution have extracutaneous manifestations, early diagnosis is vital in establishing multidisciplinary care.
PMID: 38156748
ISSN: 1525-1470
CID: 5639642
Knotted lanugo in a newborn: Cultural practices revealed [Letter]
Needle, Carli D; Ramachandran, Vignesh; Oza, Vikash S
Across the world, there are varied cultural practices applied in the newborn period that pediatric dermatologists need to be familiar with. This report details a 9-day-old girl who presented with black, spike-like hairs across the back after her mother had been rubbing breast milk on her back in a circular motion for the first 7 days of life. On dermatoscopic exam, these lesions were found to be tight bundles of lanugo hairs, consistent with a diagnosis of knotted lanugo. Improved understanding of cultural practices and newborn skin care routines is critical for diagnosis, treatment, and counseling.
PMID: 38072005
ISSN: 1525-1470
CID: 5589432
Neutrophilic dermatosis in a patient with an IKZF1 variant and a review of monogenic autoinflammatory disorders presenting with neutrophilic dermatoses [Case Report]
Guirguis, Justina; Iosim, Sonia; Jones, Derek; Likhite, Maryel; Chen, Fei; Kesserwan, Chimene; Gindin, Tatyana; Kahn, Philip J; Beck, David; Oza, Vikash S; Hillier, Kirsty
Monogenic diseases of immune dysregulation should be considered in the evaluation of children presenting with recurrent neutrophilic dermatoses in association with systemic signs of inflammation, autoimmune disease, hematologic abnormalities, and opportunistic or recurrent infections. We report the case of a 2-year-old boy presenting with a neutrophilic dermatosis, found to have a novel likely pathogenic germline variant of the IKAROS Family Zinc Finger 1 (IKZF1) gene; the mutation likely results in a loss of function dimerization defective protein based on reports and studies of similar variants. IKZF1 variants could potentially lead to aberrant neutrophil chemotaxis and development of neutrophilic dermatoses. Long-term surveillance is required to monitor the development of hematologic malignancy, autoimmunity, immunodeficiency, and infection in patients with pathogenic IKZF1 germline variants.
PMID: 38413050
ISSN: 1525-1470
CID: 5634772
Anifrolumab for Adolescent Discoid Lupus Erythematosus [Letter]
Shaw, Katharina S; Rajeh, Ahmad; Le, Todd; Kahn, Philip J; Oza, Vikash S; Arkin, Lisa M; Vleugels, Ruth Ann
PMCID:10585408
PMID: 37851448
ISSN: 2574-3805
CID: 5708302
Evolving trends in inpatient paediatric dermatology
Pineider, Juliana; Oza, Vikash S; Cipriano, Sarah D
PURPOSE OF REVIEW/OBJECTIVE:This review provides updates in the evaluation and management of key dermatologic diseases encountered in the hospitalized child. RECENT FINDINGS/RESULTS:Our understanding of dermatologic disorders in children continues to evolve. Staphylococcal scalded skin syndrome (SSSS) is a potentially severe blistering disorder typically seen in children under the age of 4 with an incidence that is increasing in the United States. Recent research has highlighted that the majority of cases are due to methicillin-sensitive Staphylococcus aureus (MSSA) and most patients can be adequately managed with beta-lactams. Toxic epidermal necrolysis (TEN) is one of the most feared dermatologic disorders. Currently, there is a lack of consensus on the most efficacious first-line systemic therapy. Etanercept is increasingly being used based on studies showing a shorter time to re-epithelization and decreased mortality. Lastly, the COVID-19 pandemic introduced the novel inflammatory condition multisystem inflammatory syndrome in children (MIS-C) in which approximately three out of four children present with a mucocutaneous eruption. Early recognition of the dermatologic features of MIS-C is important in potentially establishing a diagnosis and differentiating it from the many other causes of childhood fever and rash. SUMMARY/CONCLUSIONS:There are no clear universal treatment guidelines for these rare diagnoses, and therefore, clinicians must remain informed of the latest findings in diagnosis and therapeutics.
PMID: 37097288
ISSN: 1531-698x
CID: 5465092
Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea [Comment]
García-Romero, Maria Teresa; Tollefson, Megha; Pope, Elena; Brandling-Bennett, Heather A; Paller, Amy S; Keimig, Emily; Arkin, Lisa; Wanat, Karolyn A; Humphrey, Stephen R; Werth, Victoria P; Oza, Vikash; Jacobe, Heidi; Fett, Nicole; Cordoro, Kelly M; Medina-Vera, Isabel; Chiu, Yvonne E
IMPORTANCE/UNASSIGNED:Morphea is an insidious inflammatory disorder of the skin and deeper tissues. Determining disease activity is challenging yet important to medical decision-making and patient outcomes. OBJECTIVE/UNASSIGNED:To develop and validate a scoring tool, the Morphea Activity Measure (MAM), to evaluate morphea disease activity of any type or severity that is easy to use in clinical and research settings. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:This pilot diagnostic study was conducted from September 9, 2019, to March 6, 2020, in 2 phases: development and validation. During the development phase, 14 morphea experts (dermatologists and pediatric dermatologists) used a Delphi consensus method to determine items that would be included in the MAM. The validation phase included 8 investigators who evaluated the tool in collaboration with 14 patients with pediatric morphea (recruited from a referral center [Medical College of Wisconsin]) during a 1-day in-person meeting on March 6, 2020. MAIN OUTCOMES AND MEASURES/UNASSIGNED:During the development phase, online survey items were evaluated by experts in morphea using a Likert scale (score range, 0-10, with 0 indicating not important and 10 indicating very important); agreement was defined as a median score of 7.0 or higher, disagreement as a median score of 3.9 or lower, and no consensus as a median score of 4.0 to 6.9. During the validation phase, reliability (interrater and intrarater agreement using intraclass correlation coefficients), validity (using the content validity index and κ statistics as well as correlations with the modified Localized Scleroderma Severity Index and the Physician Global Assessment of Activity using Spearman ρ coefficients), and viability (using qualitative interviews of investigators who used the MAM tool) were evaluated. Descriptive statistics were used for quantitative variables. Data on race and ethnicity categories were collected but not analyzed because skin color was more relevant for the purposes of this study. RESULTS/UNASSIGNED:Among 14 survey respondents during the development phase, 9 (64.3%) were pediatric dermatologists and 5 (35.7%) were dermatologists. After 2 rounds, a final tool was developed comprising 10 items that experts agreed were indicative of morphea activity (new lesion in the past 3 months, enlarging lesion in the past 3 months, linear lesion developing progressive atrophy in the past 3 months, erythema, violaceous rim or color, warmth to the touch, induration, white-yellow or waxy appearance, shiny white wrinkling, and body surface area). The validation phase was conducted with 14 patients (median age, 14.5 years [range, 8.0-18.0 years]; 8 [57.1%] female), 2 dermatologists, and 6 pediatric dermatologists. Interrater and intrarater agreement for MAM total scores was good, with intraclass correlation coefficients of 0.844 (95% CI, 0.681-0.942) for interrater agreement and 0.856 (95% CI, 0.791-0.901) for intrarater agreement. Correlations between the MAM and the modified Localized Scleroderma Severity Index (Spearman ρ = 0.747; P < .001) and the MAM and the Physician Global Assessment of Activity (Spearman ρ = 0.729; P < .001) were moderately strong. In qualitative interviews, evaluators agreed that the tool was easy to use, measured morphea disease activity at a single time point, and should be responsive to changes in morphea disease activity over multiple time points. CONCLUSIONS AND RELEVANCE/UNASSIGNED:In this study, the MAM was found to be a reliable, valid, and viable tool to measure pediatric morphea activity. Further testing to assess validity in adults and responsiveness to change is needed.
PMID: 36753150
ISSN: 2168-6084
CID: 5447992
Cross-Sectional Characteristics of Pediatric-Onset Discoid Lupus Erythematosus: Results of a Multicenter, Retrospective Cohort Study
Ezeh, N; Ardalan, K; Buhr, K A; Nguyen, C; Al Ahmed, O; Ardoin, S P; Barton, V; Bell, S; Brandling-Bennett, H; Castelo-Soccio, L; Chiu, Y E; Chong, B F; Lara-Corrales, I; Cintosun, A; Curran, M L; Diaz, L Z; Elman, S A; Faith, E Fernandez; Garcia-Romero, M T; Grossman-Kranseler, J; Hogeling, M; Hudson, A D; Hunt, R D; Ibler, E M; Marques, M C; Monir, R L; Oza, V; Paller, A S; Putterman, E; Rodriguez-Salgado, P; Schoch, J J; Truong, A; Wang, J; Lee, L Wine; Vleugels, R A; Klein-Gitelman, M S; von Scheven, E; Werth, V P; Arkin, L M
• Discoid lupus may be associated with SLE. In this study, most children with discoid lupus did not have systemic disease. Concurrent SLE was highest in female adolescents (>10 years of age) with generalized discoid lupus, who had clinically aggressive disease. • Discoid lupus in adolescence should prompt thorough evaluation for SLE.
PMID: 35487332
ISSN: 1097-6787
CID: 5217732
Molluscum Contagiosum Therapeutics-New Options May Be Around the Corner
Oza, Vikash S
PMID: 35830172
ISSN: 2168-6084
CID: 5279902
Focal Palmoplantar Keratoderma and Gingival Keratosis Caused by a KRT16 Mutation [Letter]
Zaki, Theodore D; Boyden, Lynn M; Mathes, Erin; Hu, Rong-Hua; Zhou, Jing; Loring, Erin; North, Jeffrey; Oza, Vikash; Choate, Keith A
PMID: 36179229
ISSN: 2326-6929
CID: 5351232
Morbilliform Eruptions in the Hospitalized Child
Haber, Jessica S; Cipriano, Sarah D; Oza, Vikash S
Morbilliform eruptions inspire a broad and varied differential spanning across inflammatory and infectious categories. The goal of this article is to help the clinician develop an approach toward the pediatric patient with a morbilliform eruption in the emergency room or hospital setting. The authors review several high-yield clinical scenarios with a focus on recently emerging and reemerging childhood diagnoses.
PMCID:8896762
PMID: 35366972
ISSN: 1558-0520
CID: 5190732